Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 7/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10642276 | 0.89 | FBP1 (0.51) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL13804961 | 0.87 | KMT2A (0.45) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL2612654 | 0.86 | KMT2A (0.58) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL4185645 | 0.83 | KMT2A (0.51) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL8257058 | 0.83 | KMT2A (0.51) | KMT2AALDH1A1HCRTR2FBP1 | |
| SCHEMBL3256506 | 0.82 | KMT2A (0.58) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL17277540 | 0.80 | KMT2A (0.49) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL10567359 | 0.80 | KMT2A (0.49) | KMT2AALDH1A1HCRTR2FBP1CNR2 | |
| SCHEMBL11331630 | 0.79 | HSD17B1 (0.47) | ALDH1A1CYP3A4CYP2C9CYP2C19PSIP1 | |
| SCHEMBL1272243 | 0.79 | PTGDR2 (0.48) | KMT2AALDH1A1HCRTR2MEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-9750740-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | Kanos Pharmaceuticals, Inc. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2017-04-06 | — | — | US | disclosed |
| US-9512122-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2016-04-07 | — | — | US | disclosed |
| US-9199994-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | KAROS PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2015-03-19 | — | — | US | disclosed |
| US-20140088053-A1 | INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 | UNIVERSITé LAVAL (CA) | 2014-03-27 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-7101892-B2 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. | 2006-09-05 | — | — | US | disclosed |
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | MERCK SHARP & DOHME LTD. (GB) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229864-A1 | Sulfone derivatives as 5-HT7 receptor ligands | HTR7, HTR2C, HTR1A | KMT2A 2168/4885ALDH1A1 1138/4885HCRTR2 22/4885 |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | KMT2A 3777/4885ALDH1A1 3797/4885HCRTR2 3176/4885 |
| US-20150080393-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | KMT2A 1610/4885ALDH1A1 433/4885HCRTR2 284/4885 |
| US-20170095476-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | KMT2A 1610/4885ALDH1A1 433/4885HCRTR2 284/4885 |
| US-20160096836-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | KMT2A 1610/4885ALDH1A1 433/4885HCRTR2 284/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | KMT2A 1610/4885ALDH1A1 433/4885HCRTR2 284/4885 |
| US-20140088053-A1 | INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 | HSD17B11, HSD17B1, HSD17B3 | KMT2A 1815/4885ALDH1A1 140/4885HCRTR2 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.